Dmitriy
@dmitriy.bsky.social
Researcher at the Institute for Clinical and Economic Review (ICER), an independent nonprofit that analyzes the cost-effectiveness of drugs
Creator of Demography feed: https://tinyurl.com/bskydemo
Creator of Demography feed: https://tinyurl.com/bskydemo
Hi Nick, happy to help with beta testing.
July 10, 2025 at 2:17 AM
Hi Nick, happy to help with beta testing.
@charlespiller.bsky.social recently wrote a great book on ALZ and scientific misconduct in the field
March 3, 2025 at 5:29 PM
@charlespiller.bsky.social recently wrote a great book on ALZ and scientific misconduct in the field
February 27, 2025 at 7:59 PM
Thanks for reaching out, Stefan. Just added you 😊
February 7, 2025 at 10:58 PM
Thanks for reaching out, Stefan. Just added you 😊
The Wayback Machine by the @archive.org does a great job of backing up ClinicalTrials.gov (and millions of other sites!)
Example: web.archive.org/web/20241116...
Example: web.archive.org/web/20241116...
ClinicalTrials.gov
web.archive.org
January 29, 2025 at 2:04 PM
The Wayback Machine by the @archive.org does a great job of backing up ClinicalTrials.gov (and millions of other sites!)
Example: web.archive.org/web/20241116...
Example: web.archive.org/web/20241116...
He looks like a very kind man. So sorry for your loss, Gabe.
January 9, 2025 at 12:57 AM
He looks like a very kind man. So sorry for your loss, Gabe.
Great picks! Based on your list, I think you may also enjoy Timberborn 🦫
December 25, 2024 at 4:58 PM
Great picks! Based on your list, I think you may also enjoy Timberborn 🦫
Havis and snow are a beautiful combo. 😍
December 21, 2024 at 2:44 PM
Havis and snow are a beautiful combo. 😍
🧪A second drug for transthyretin amyloid cardiomyopathy just got approved a week early.
At $225K/year, it's more accessible than Pfizer's $268K Vyndaqel but still far exceeds ICER's recommended $13.6K-$39K range.
Big news for the 50,000+ patients in US, but pricing debate continues.
At $225K/year, it's more accessible than Pfizer's $268K Vyndaqel but still far exceeds ICER's recommended $13.6K-$39K range.
Big news for the 50,000+ patients in US, but pricing debate continues.
BridgeBio wins FDA approval for heart disease drug
The FDA approved a new medicine from BridgeBio for patients with ATTR-CM, a progressive heart disease
www.statnews.com
November 23, 2024 at 12:58 AM
Summary of ICER's October ATTR-CM report here: icer.org/wp-content/u...
icer.org
November 23, 2024 at 12:42 AM
Summary of ICER's October ATTR-CM report here: icer.org/wp-content/u...
Not sure what your tolerance is for paid search engines, but @kagi.com recently updated their image search to have a "No AI" filter that's perfect for your use case.
November 22, 2024 at 10:19 PM
Not sure what your tolerance is for paid search engines, but @kagi.com recently updated their image search to have a "No AI" filter that's perfect for your use case.
The grey lit and additional citations are definitely a plus!
Are you familiar with openalex.org ?
I've been slowly migrating my GScholar searches over to OA due to them being open-source/nonprofit.
Are you familiar with openalex.org ?
I've been slowly migrating my GScholar searches over to OA due to them being open-source/nonprofit.
OpenAlex
openalex.org
November 21, 2024 at 5:32 PM
The grey lit and additional citations are definitely a plus!
Are you familiar with openalex.org ?
I've been slowly migrating my GScholar searches over to OA due to them being open-source/nonprofit.
Are you familiar with openalex.org ?
I've been slowly migrating my GScholar searches over to OA due to them being open-source/nonprofit.
Welcome, Kent! You may find the demography feed useful to connect with colleagues bsky.app/profile/dmit...
November 21, 2024 at 3:35 PM
Welcome, Kent! You may find the demography feed useful to connect with colleagues bsky.app/profile/dmit...
